Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

abemaciclib

- PMLiVE

Pfizer starts Ibrance trials in early breast cancer

Hopes to encourage wider use of breakthrough drug

Roche's Perjeta pertuzumab

European approval for Roche’s next-gen breast cancer drug

Perjeta now available in EU for use before surgery in early stage aggressive breast cancer

- PMLiVE

NHS sponsors charity on metastatic breast cancer study

Breast Cancer Now to study tissue shortly after death

- PMLiVE

AZ and BMS earn ASCO plaudits

Both firms tout new combination therapies at the annual cancer congress in Chicago

- PMLiVE

AZ escapes censure over cancer tweet

Firm did not breach UK’s Code of Practice over survival statistics post

- PMLiVE

Pfizer breast cancer drug shines in latest trial

Study with Ibrance stopped early because of its success

- PMLiVE

Nektar hit by breast cancer trial setback

NKTR-102 failed to meet phase III targets

- PMLiVE

Pfizer’s Ibrance wins early breast cancer approval in US

FDA’s decision come two months ahead of schedule

- PMLiVE

Double trial disappointment for Roche

Discontinues Alzheimer’s programme and finds Kadcyla no better than Herceptin in certain breast cancer

- PMLiVE

Cyramza gets FDA green light in lung cancer

Drug steadily being approved for further uses

- PMLiVE

Novartis’ Afinitor fails frontline breast cancer trial

Drug already approved to treat HER2-negative breast cancer

- PMLiVE

Merck to start major trial of Keytruda in breast cancer

PD-1 immunotherapy is already available as treatment for melanoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links